ESTRO 2024 - Abstract Book

S2321

Clinical - Urology

ESTRO 2024

surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. Apr 11;395(10231):1208 – 1216

424

Proffered Paper

SBRT after progression during abiraterone plus prednisone. A subgroup analysis from ARTO trial

Giulio Francolini 1 , Vanessa Di Cataldo 1 , Pietro Garlatti 2 , Beatrice Detti 1 , Saverio Caini 3 , Alessio Bruni 4 , Gianluca Ingrosso 5 , Rolando Maria D'angelillo 6 , Anna Rita Alitto 7 , Matteo Augugliaro 8 , Luca Triggiani 9 , Silvana Parisi 10 , Gaetano Facchini 11 , Gabriele Simontacchi 1 , Isacco Desideri 2 , Icro Meattini 2 , Giulia Marvaso 12,13 , Barbara Alicja Jereczek Fossa 12,13 , Filippo Alongi 14 , Fabio Arcidiacono 15 , Andrea Lancia 16 , Domenico Genovesi 17 , Ciro Franzese 18 , Marta Scorsetti 18 , Lorenzo Livi 2 1 Azienda Ospedaliero Universitaria Careggi, Radiation Oncology Unit, Oncology Department, Florence, Italy. 2 University of Florence, Department of Biomedical, Experimental and Clinical Sciences "M. Serio", Florence, Italy. 3 Institute for Cancer Research, Prevention and Clinical Network (ISPO), Cancer Risk Factors and Lifestyle Epidemiology Unit, Florence, Italy. 4 Radiation Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Florence, Italy. 5 Department of Medicine and Surgery, University of Perugia, Radiation Oncology Section, Perugia, Italy. 6 University of Rome "Tor Vergata", Radiation Oncology, Department of Biomedicine and Prevention, Rome, Italy. 7 Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy. 8 Azienda USL-IRCCS di Reggio Emilia, Unit of Radiotherapy, Reggio Emilia, Italy. 9 Università degli Studi di Brescia, Department of Radiation Oncology, Brescia, Italy. 10 University of Messina, Department of Biomedical, Dental Science and Morphological and Functional Images, Messina, Italy. 11 SM delle Grazie Hospital, Medical Oncology Unit, Pozzuoli, Italy. 12 IEO European Institute of Oncology IRCCS, Department of Radiation Oncology, Milan, Italy. 13 University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy. 14 IRCCS Sacro Cuore Don Calabria Hospital, Department of Advanced Radiation Oncology, Negrar, Verona, Italy. 15 Radiation Oncology Centre, S. Maria Hospital, Terni, Italy. 16 Fondazione IRCCS Policlinico San Matteo, Department of Radiation Oncology, Pavia, Italy. 17 Department of Radiation Oncology, Department of Radiation Oncology, Chieti, Italy. 18 Humanitas Clinical and Research Center – IRCCS, Department of Radiotherapy and Radiosurgery, Rozzano, Milan, Italy

Purpose/Objective:

ARTO (NCT03449719) is a multicentre, randomized phase II trial testing the benefit of upfront stereotactic body radiation therapy (SBRT) in addition to abiraterone acetate plus prednisone (AAP) in oligometastatic Castration Resistant Prostate Cancer (CRPC) patients. Benefit was measured in terms of biochemical response and Progression Free Survival (PFS) in the experimental arm [1]. However, oligometastatic status persisted in a significant number of patients after progression under first line abiraterone plus prednisone treatment. Considering that patients may still benefit from SBRT in this setting, we performed a secondary analysis focusing on impact of SBRT received after progression in these cases, in order to explore if metastasis directed therapy maintained its impact in a later stage of disease.